Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

March 1, 2011

Primary Completion Date

January 21, 2013

Study Completion Date

March 1, 2013

Conditions

Chronic Hepatitis C

Interventions

DRUG

Peginterferon Alfa-2A

180 mcg, subcutaneous injection, once weekly

DRUG

Ribavirin Oral Product

15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)